Sophia Genetics Unveils AI-Powered Digital Twins to Advance Precision Oncology and Improve Treatment Decision-Making

Reuters10-16
Sophia Genetics Unveils AI-Powered Digital Twins to Advance Precision Oncology and Improve Treatment Decision-Making

SOPHiA GENETICS has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered technology designed to enhance intelligent decision-making in oncology. The Digital Twins platform creates dynamic virtual representations of individual patients using clinical, biological, imaging, and genomic data, enabling oncologists to simulate treatment responses and disease trajectories in real time. The technology aims to help match patients with the most effective therapies, reduce exposure to ineffective treatments, and improve precision medicine in cancer care. The announcement states that Digital Twins is launching for lung cancer on the SOPHiA DDM™ Platform, with additional cancer types to follow. These results and the new platform will be presented at the ESMO conference in Berlin, Germany, from October 17 to 21.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE99202) on October 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment